Cargando…
Effect of tobacco use on disease activity and DMT discontinuation in multiple sclerosis patients treated with dimethyl fumarate or fingolimod
BACKGROUND: Tobacco exposure is a modifiable risk factor for multiple sclerosis (MS). Studies evaluating the relationship between tobacco, disease activity, and disease modifying therapy (DMT) persistence yielded conflicting results. We sought to address this issue with data from clinical practice....
Autores principales: | Hersh, Carrie M, Harris, Haleigh, Ayers, Malissa, Conway, Devon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7557793/ https://www.ncbi.nlm.nih.gov/pubmed/33110616 http://dx.doi.org/10.1177/2055217320959815 |
Ejemplares similares
-
Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers
por: Vollmer, Brandi, et al.
Publicado: (2018) -
Effect of switching from natalizumab to moderate- vs high-efficacy DMT in clinical practice
por: Hersh, Carrie M., et al.
Publicado: (2020) -
Duration of natalizumab therapy and reasons for discontinuation in a
multiple sclerosis population
por: Conway, Devon S, et al.
Publicado: (2020) -
A case of presumed herpes keratouveitis in a patient treated with
fingolimod
por: Ayers, Malissa C, et al.
Publicado: (2016) -
Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up
por: Hersh, Carrie M, et al.
Publicado: (2017)